Vasoactive liabilities are typically assayed using wire myography, which is limited by its high cost and low throughput. To meet the demand for higher throughput in vitro alternatives, this study introduces a magnetic 3D bioprinting-based vasoactivity assay. The principle behind this assay is the magnetic printing of vascular smooth muscle cells into 3D rings that functionally represent blood vessel segments, whose contraction can be altered by vasodilators and vasoconstrictors. A cost-effective imaging modality employing a mobile device is used to capture contraction with high throughput. The goal of this study was to validate ring contraction as a measure of vasoactivity, using a small panel of known vasoactive drugs. In vitro responses of the rings matched outcomes predicted by in vivo pharmacology and were supported by immunohistochemistry. Altogether, this ring assay robustly models vasoactivity, which could meet the need for higher throughput in vitro alternatives.

Background and PurposeWhile the molecular pathways of baclofen toxicity are understood, the relationships between baclofen‐mediated perturbation of individual target organs and systems involved in cardiovascular regulation are not clear. Our aim was to use an integrative approach to measure multiple cardiovascular‐relevant parameters [CV: mean arterial pressure (MAP), systolic BP, diastolic BP, pulse pressure, heart rate (HR); CNS: EEG; renal: chemistries and biomarkers of injury] in tandem with the pharmacokinetic properties of baclofen to better elucidate the site(s) of baclofen activity.Experimental ApproachHan‐Wistar rats were administered vehicle or ascending doses of baclofen (3, 10 and 30 mg·kg−1, p.o.) at 4 h intervals and baclofen‐mediated changes in parameters recorded. A pharmacokinetic–pharmacodynamic model was then built by implementing an existing mathematical model of BP in rats.Key ResultsFinal model fits resulted in reasonable parameter estimates and showed that the drug acts on multiple homeostatic processes. In addition, the models testing a single effect on HR, total peripheral resistance or stroke volume alone did not describe the data. A final population model was constructed describing the magnitude and direction of the changes in MAP and HR.Conclusions and ImplicationsThe systems pharmacology model developed fits baclofen‐mediated changes in MAP and HR well. The findings correlate with known mechanisms of baclofen pharmacology and suggest that similar models using limited parameter sets may be useful to predict the cardiovascular effects of other pharmacologically active substances.

Doxorubicin (DOX) is a potent and effective broad-spectrum anthracycline antitumor agent, but its clinical usefulness is restricted by cardiotoxicity. This study compared pharmacokinetic, functional, structural and biochemical effects of single dose DOX bolus or 3-h continuous iv infusion (3-h iv) in the Han–Wistar rat to characterize possible treatment-related differences in drug safety over a 72 h observation period. Both DOX dosing paradigms significantly altered blood pressure, core body temperature and QA interval (indirect measure of cardiac contractility); however, there was no recovery observed in the bolus iv treatment group. Following the 3-h iv treatment, blood pressures and QA interval normalized by 36 h then rose above baseline levels over 72 h. Both treatments induced biphasic changes in heart rate with initial increases followed by sustained decreases. Cardiac injury biomarkers in plasma were elevated only in the bolus iv treatment group. Tissue cardiac injury biomarkers, cardiac mitochondrial complexes I, III and V and cardiac mitochondrial sphingolipids were decreased only in the bolus iv treatment group. Results indicate that each DOX dosing paradigm deregulates sinus rhythm.However, slowing the rate of infusion allows for functional compensation of blood pressure and may decrease the likelihood of cardiac myocyte necrosis via a mechanism associated with reduced mitochondrial damage.

The current standard for studying pharmacodynamics on vascular smooth muscle contractility is wire myography with ex vivo tissue, which suffers from high cost low throughput, limiting its widespread use. Yet, in vitro alternatives are insufficient, as they are commonly two-dimensional (2D) monolayers on rigid surfaces unlike the soft vasculature. Thus, a rapid, robust in vitro assay is needed that mimics the native three-dimensional (3D) environment, while yielding high data throughput. Towards that goal, we introduce an 3D in vitro assay in which cellularized vascular "rings" are rapidly and magnetically bioprinted. In the assay, cells are incubated with magnetic nanoparticles to render them magnetic, then printed into 3D rings (1.5 x 10^5 cells/ring) in 96-well plates. The rings will then contract or dilate over a short amount of time (<5 h) in a dose-dependent manner visually similar to vessel contraction and dilation (Fig. 1A). This measurement is label-free, meaning that the rings can be experimented on afterwards to explore pharmacodynamics. Moreover, this assay is captured using an iPod-based imaging system programmed to take images of whole plates (Fig. 1B) instead of imaging individual wells under a microscope. This assay was validated for the evaluation of drug efficacy by measuring contractility in 3D bioprinted rings of A10 rat vascular smooth muscle cells. The compounds tested were either vasodilators (blebbistatin, forskolin, verapamil) or vasoconstrictors (norepinephrine, phenylephrine, U46619). Ring contraction was compared to the presence of phosphorylated myosin light chain-2 which is related to smooth muscle concentration. Furthermore, the gene expression profiles of rings exposed to specific compounds are compared to negative controls. The result of this study is the validation of the vascular assay that rapidly prints 3D environments similar to the native blood vessel, and efficiently measures smooth muscle contraction.

Current diagnosis of drug-induced kidney injury (DIKI) primarily relies on detection of elevated plasma creatinine (Cr) or blood urea nitrogen (BUN) levels; however, both are indices of overall kidney function and changes are delayed with respect to onset of nephron injury. Our aim was to investigate whether early changes in new urinary DIKI biomarkers predict plasma Cr, BUN, renal hemodynamic and kidney morphological changes associated with kidney injury following a single dose of cisplatin (CDDP) using an integrated platform in rodent. Conscious surgically prepared male Han Wistar rats were given a single intraperitoneal dose of CDDP (15mg/kg). Glomerular filtration rate (GFR), effective renal plasma flow (ERPF), urinalysis, DIKI biomarkers, CDDP pharmacokinetics, blood pressures, heart rate, body temperature and electroencephalogram (EEG) were measured in the same vehicle- or CDDP-treated animals over 72h. Plasma chemistry (including Cr and BUN) and renal tissues were examined at study termination. Cisplatin caused progressive reductions of GFR, ERPF, heart rate and body temperature from day 1 (0-24h). DIKI biomarkers including alpha-glutathione S-transferase (α-GST) significantly increased as early as 6h post-dose, which preceded significant declines of GFR and ERPF (24h), increased plasma Cr and BUN (72h), and associated with renal acute tubular necrosis at 72h post-dose. The present study adds to the current understanding of CDDP action by demonstrating that early increases in urinary excretion of α-GST predict DIKI risk following acute exposure to CDDP in rats, before changes in traditional DIKI markers are evident.